Lonza will assist ALSA Ventures’ portfolio companies with services supporting de-risking, early development and manufacturing of next-generation modalities.
Lonza will provide kilogram-scale synthesis, purification and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply.
Collaboration to support clinical development, regulatory, commercial and real-world evidence to accelerate the development of new indications for VYVGART.